옵션 체인은 다양한 행사가격과 만기일에 대한 Ibotta의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Ibotta에 대한 시장 심리를 평가합니다..

Ibotta (NYSE:IBTA) 주식, 옵션 체인

IBOTTA INC-CL A

Ibotta

Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).

Deepseek,Ai,App,Seen,On,The,Smartphone,And,Finger,Is

Equities

Large Cap

AAPL

AMZN

BIDU

FXCOF

GOOG

IBTA

INTC

IRBT

NVDA

QCOM

SOUN

SSNLF

소비자 기술 뉴스 (3월 17일~21일): 구글의 위즈 인수 계획, 미국에서 딥시크 금지 조치, 엔비디아의 GTC 2025 행사 등

소비자 기술 뉴스 (3월 17일~21일): 구글의 위즈 인수 계획, 엔비디아의 GTC 2025 행사 등

Cathie Wood Smelling AI Opportunity? Ark Invest Buys Tempus AI Dip, Scoops Up Over $13 M Worth Of Stock

News

Markets

ETFs

ARKF

ARKG

ARKK

ARKW

CDNA

GTLB

NTLA

PATH

PRME

RBLX

RPTX

2025년 3월 14일 금요일, 캐시 우드가 이끄는 아크 인베스트가 깃랩(NASDAQ:GTLB), 인텔리아 테라퓨틱스(NGM:NTLA), 프라임 메디슨(NGM:PRME), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 로블록스(NYSE:RBLX), 리페어 테라퓨틱스(NASDAQ:RPTX) 및 케어DX(NASDAQ:CDNA)에 대해 큰 매매를 했다.

아크 인베스트: 유아이패스와 로블록스 주식을 계속 처분, 깃랩과 아이보타를 매수

Cathie Wood's Buys The Dip In Tempus AI, Coinbase But Sells Ark's Bitcoin ETF Shares Amid Crypto Meltdown

Tech

ABSI

ARKQ

PSNL

ROKU

RXRX

금요일, 캐시 우드가 이끄는 아크 인베스트가 몇 가지 주요 거래를 진행했다. 이 거래는 로블록스(NYSE:RBLX), 로쿠(NASDAQ:ROKU), 유아이패스(NYSE:PATH), 아이보타(NYSE:IBTA), 퍼스널리스(NGM:PSNL), 앱시(NASDAQ:ABSI) 그리고 리커전 파마슈티컬스(NASDAQ:RXRX)와 같은 주식들에 대한 활동이 두드러졌다.

캐시 우드의 아크 인베스트가 시장 하락에 로블록스, 로쿠 및 유아이패스 매도

Ibotta Inc

Management

Koppers Holdings Appoints James A. Sullivan President; Effective June 1, 2025

ALMS

Alumis Completes Patient Enrollment In Pivotal Phase 3 ONWARD Clinical Program Of ESK-001 For Treatment Of Moderate-To-Severe Plaque Psoriasis

President Donald Trump has been dealt a significant blow to his trade policies, with a federal court ruling against his authority to impose global tariffs. However, the president is likely to find a workaround to this setback.
What Happened: Goldman Sachs economists believe that the court&#8217;s decision will only be a temporary obstacle, as the Trump administration has other legal ways of imposing tariffs. These include Section 122 of the Trade Act of 1974, Section 301 investigations and Section 338 of the Trade Act of 1930, <a href="https://www.cnbc.com/2025/05/29/trump-expected-to-find-a-workaround-after-trade-court-blocks-tariffs.html">reported</a> CNBC.
Section 122 allows the administration to swiftly impose tariffs—up to 15%—without a formal investigation, offering a quick workaround to court obstacles. However, Goldman analysts note the measure would expire after 150 days unless Congress intervenes.
Meanwhile, Section 232 tariffs on steel, aluminum, and autos may be expanded to other sectors, while Section 338 permits the president to impose up to 50% tariffs on imports from countries that discriminate against the U.S.
The White House could shift its focus from targeting specific countries to targeting industries instead — an approach that rests on more solid legal footing, as per Goldman Sachs.
Steven Blitz, TS Lombard&#8216;s chief U.S. economist, opined, "The first thing he will probably do is an emergency appeal to the Supreme Court … wanting to get a ruling from them that basically says you can keep these tariffs in place while the appeals process runs through."
Speaking about the Trump Administration&#8217;s appeal within minutes, Deutsche Bank's Jim Reid said a note, "We should say at the outset that this is hardly the end of this story,&#8221; reported Fortune. 
SEE ALSO: <a href="https://benzinga.com/25/05/45664572/us-stocks-likely-to-open-higher-after-federal-court-invalidates-trumps-tariffs-without-tariff-revenues-there-is-a-big-beautiful-hole-in-the-big-beautiful-budget-bill-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher After Federal Court Blocks Trump&#8217;s Tariffs: &#8216;Without Tariff Revenues, There Is A Big Beautiful Hole In The Big Beautiful Budget Bill,&#8217; Says Expert</a>
Why It Matters: The court&#8217;s ruling could have a significant impact on the administration&#8217;s trade strategies. The decision, delivered by the U.S. Court of International Trade, could potentially <a href="https://www.benzinga.com/news/25/05/45660322/trump-tariffs-struck-down-by-federal-court-major-blow-to-white-houses-trade-strategy-report">halt </a>the administration&#8217;s trade war efforts.
Legal experts and economists have supported the court&#8217;s decision stating that the President was wrong to claim a virtually unlimited power to impose tariffs. However, some economists in the past stated that Trump tariffs are &#8216;addictive&#8217; and could remain in place even if the Democrats come <a href="https://www.benzinga.com/news/25/05/45556999/addictive-trump-tariffs-are-here-to-stay-even-if-democrats-come-back-to-power-says-wharton-professor">back to power</a> as they may not want to discontinue the lucrative revenue stream. 
Meanwhile, China has already responded to the court&#8217;s decision, calling on the United States to <a href="https://www.benzinga.com/markets/25/05/45664337/china-tells-us-to-entirely-revoke-wrongful-unilateral-tariffs-after-court-blocks-trumps-liberation-day-levies">entirely withdraw</a> the unilateral tariff measures that the court blocked.
Despite the setback, Trump is expected to find a way around the court&#8217;s ruling, potentially using other legal means to impose tariffs. The market reaction to the ruling has been mixed, with equity&nbsp;markets around the world broadly&nbsp;rising, while the reaction in Europe has been more muted.
During Thursday&#8217;s pre-market, The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and  Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.06% and 1.55%, respectively.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/25/05/45661076/peter-schiff-challenges-jd-vances-bitcoins-safe-haven-assertion-urges-him-to-implement-policies-that-reduce-the-need-to-hedge" target="_blank" rel="noreferrer noopener">JD Vance Said Bitcoin Created Wealth, Peter Schiff Says It Did No Such Thing: &#8216;What Has Happened Is A Massive Transfer Of …&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

'Hardly The End Of This Story:' Trump Has Several Legal Options To Maintain Tariffs Despite Federal Court Ruling, Experts Say

WGRX

Wellgistics Health Announces Preliminary Inclusion In Russell 2000 And Russell 3000 Indexes, As Part Of 2025 Russell US Indexes Annual Reconstitution

<ul>
<li>Strategic Expansion into Turkiye: DeFi Technologies enters collaboration with Misyon Bank and Misyon Kripto to work to introduce ETPs, offering Turkish investors alternative access to digital assets like Bitcoin and Ethereum.</li>
<li>Tapping a High-Growth Market: Turkiye ranks among the top countries in crypto adoption, driven by inflation, currency volatility, and a digitally native population, with over 50% of investor population holding digital assets.</li>
<li>Global Growth Momentum: The partnership aligns with DeFi Technologies' broader strategy to expand across the Middle East, Asia, and Africa through key institutional partnerships and localized product offerings.</li>
</ul>
&nbsp;"DeFi Technologies"(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"),&nbsp; and its subsidiary Valour Inc. ("Valour"), a leading issuer of exchange traded products ("ETPs") that provide simplified access to digital assets, is pleased to announce its strategic collaboration with Misyon Bank and its crypto trading subsidiary Misyon Kripto prepare for introducing a series of innovative digital investment products to Turkish investors.

Contracts

DEFT

DeFi Technologies And Misyon Enters Agreement To Launch Innovative Digital Asset Investment Products In Turkiye

STRM

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

One of the major dealers of Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) has reportedly shut down its operations across multiple cities in China as the company expands into the European market.
What Happened: Over 20 stores of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival in China's eastern Shandong province, owned by a company called Qiancheng Holdings, were shut, according to a Reuters report citing Chinese state-owned media on Thursday.
The company shutting down the stores in over 4 major cities has affected over 1,000 customers with warranty and after-sales service-related woes, the report suggests.
Qiancheng cited changes to BYD's dealer policies, which increased the pressure on the company's cash flow. However, a representative from BYD cited in the Reuters report suggests that Qiancheng's rapid expansion led to the crisis instead.
BYD did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: BYD has been steadily expanding its footprint on the global front, with the automaker setting up <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">a manufacturing facility</a> in Hungary, which can annually produce over 200,000 EVs.
BYD <a href="https://www.benzinga.com/25/05/45564693/byd-outsells-elon-musks-tesla-amid-european-plans-shift-into-gear">also overtook Tesla </a>for the first time in sales in the European market, registering marginally better sales in April 2025 than Elon Musk's company.
However, the Chinese automaker has recently landed in legal trouble as BYD faces a <a href="https://www.benzinga.com/government/regulations/25/05/45639357/teslas-chinese-rival-byd-sued-for-45-million-over-alleged-human-trafficking-slave-like-conditions-at-brazil-factory-site">$45 million lawsuit</a> in Brazil for alleged "human-trafficking" and "slave-like" conditions at the construction site in Brazil's Bahia state.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/05/45611701/chinese-regulators-will-meet-tesla-rival-byd-other-companies-to-discuss-zero-mile-used-cars-report">Chinese Regulators Will Meet Tesla Rival BYD, Other Companies To Discuss &#8216;Zero Mile&#8217; Used Cars: Report</a></li>
</ul>
Photo courtesy: Tada Images/Shutterstock

Asia

BYDDY

TSLA

Over 20 BYD Dealerships Shut Down In China Amid Expansion To Europe, Impacting 1,000+ Customers: Report

QNTM

Quantum Biopharma Licensee Celly Nutrition Changes Name To Unbuzzd Wellness Inc. Effective May 23, 2025

DA Davidson analyst Tom White upgrades eXp World Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPI#NASDAQ">EXPI</a>) from Neutral to Buy and announces $10.75 price target.

Upgrades

Price Target

Analyst Ratings

EXPI

DA Davidson Upgrades eXp World Holdings to Buy, Announces $10.75 Price Target

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit firm MNP LLP ("MNP") effective May 20, 2025, to conduct Public Company Accounting Oversight Board ("PCAOB") audits of the Company's financial statements in preparation for a possible initial public offering ("IPO"). The Company's predecessor auditor, Stern &amp; Lovrics LLP (the "Predecessor Auditor") resigned effective May 20, 2025, at the Company's request, and the Company's board of directors, upon the audit committee's recommendation, appointed MNP to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.

CSE:QNTM

Quantum BioPharma's Unbuzzd Wellness Inc. Engages MNP for PCAOB Audits Ahead Of Potential IPO, Replacing Stern & Lovrics

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and raises the price target from $7 to $9.

TSHA

Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $9

Raymond James analyst Srini Pajjuri maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Outperform and lowers the price target from $130 to $110.

MRVL

Raymond James Maintains Outperform on Marvell Tech, Lowers Price Target to $110

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$2.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$2.5 Price Target

Earnings

CORRECTION: Aurora Mobile Q1 Adj. EPADS $(0.06) Down From $(0.04) YoY, Sales $12.26M Up From $8.94M YoY

JetBlue (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) and United (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) today announced Blue Sky: a new and unique collaboration that gives customers of both airlines even more options to find flights that fit their plans as well as new opportunities to earn and use MileagePlus&#xAE; miles and TrueBlue points across both airlines.

JBLU

JetBlue and United Team Up to Expand Flight Options and Shared Rewards

Guidance

ALAR

Alarum Technologies Sees Q2 Sales $7.663M-$8.137M vs $8.35M Est

WIIM

Tesla shares are trading higher after CEO Elon Musk announced his role as Special Government Employee has concluded.

BOSC

BOS CEO Says 'Based on our first quarter performance and contracted backlog, we are optimistic about surpassing our full-year outlook for 2025, which are revenues of $44 million and net income of $2.5 million,'

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) with a Buy and maintains $10 price target.

Reiteration

DMAC

HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $10 Price Target

Earnings Misses

Alarum Technologies Q1 Adj. EPADS $0.16, Inline, Sales $7.13M Miss $7.87M Estimate

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ibotta, Inc of Class Action Lawsuit and Upcoming Deadlines - IBTA

Legal

IBTA DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ibotta, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – IBTA

IBTA Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IBTA

IBOTTA, INC. (NYSE: IBTA) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Ibotta, Inc. Investors of Upcoming Deadline

Small Cap

IBTA Investors Have Opportunity to Lead Ibotta, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Ibotta, Inc. (IBTA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

IBTA Deadline: IBTA Investors Have Opportunity to Lead Ibotta, Inc. Securities Lawsuit

IBTA Investors Have the Opportunity to Lead the Ibotta Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Shareholders that lost money on Ibotta, Inc.(IBTA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Comments

Ibotta

Ibotta (IBTA) 옵션

Ibotta (NYSE:IBTA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌